Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INDSWFTLAB.NS
Strong BuyPremium GrowerInd-Swift Laboratories Limited · Healthcare · India · $356M · Avg Vol: $7M/d
81
StockRankGet insider-trade alerts
Q
54
V
27
M
97
P/E (TTM)
57.8x
ROE
3.1%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 12.1B | 17.1B | 5.6B | 6.3B | -19.7% | 6.7B |
| EPS (INR) | -4.28 | 91.18 | 37.25 | 5.16 | -76.2% | 6.72 |
| Shares | 59.1M | 59.1M | 60.6M | 86.8M | +47.0% | 87.0M |
| Debt | 8.6B | 2.2B | 329.8M | 179.1M | -72.5% | 205.0M |
| Equity | 6.8B | 8.1B | 11.7B | 13.8B | 26.6% | — |
| Op CF | 1.9B | -1.9B | -286.9M | -681.7M | — | -681.7M |
| Inv CF | -133.7M | -271.5M | -1.1B | -726.8M | — | — |
| Fin CF | -1.9B | 6.6B | 724.2M | 1.4B | — | — |
Loading 1Y...
PRICE (1Y)+73.8%
SMA 50SMA 200
Close
$4.09
RSI (14)
73.8
52W High
$4.25
From 52W High
1.0%
SCORE BREAKDOWN
Quality
54
ROIC
5.3%56.2
ROE
3.1%50.8
GP/Assets
23.1%50.3
Op. Margin
13.5%71.5
FCF/Assets
-9.3%30.4
Piotroski
316.1
Int. Cover
50.0x89.2
D/E Ratio
0.01x82.5
Current Ratio
3.80x63.8
Value
27
P/E (TTM)
57.8x18.3
EV/EBITDA
41.9x14.6
P/FCF
—N/A
P/B
2.3x55.9
P/S
5.0x41.4
Div Yield
—N/A
Momentum
97
52W High %
96%95.7
RS 6M
177%99.0
SMA 50/200
1.66x99.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
181%91.3
FUNDAMENTALS
Market Cap
$356M
P/E (Forward)
—
Gross Margin
57.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INDSWFTLAB.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited(you) | $356M | 81 | Strong Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $406M | 80 | Strong Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| HIKAL.NS | Hikal Limited | $320M | 75 | Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $489M | 79 | Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| FDC.NS | FDC Limited | $594M | 76 | Buy |
| GUFICBIO.NS | Gufic Biosciences Limited | $466M | 71 | Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%